Abstract:Objectives: The objectives were to examine the correlation between soluble Fas (sFas) level and apoptosis of T cells in peripheral blood and peritoneal fluid of patients with ovarian carcinoma and to investigate the possible sFas effect on T cell apoptosis.Study design: Patients with stages I-II ovarian carcinoma (n = 10) and patients with stages III-IV ovarian carcinoma (n = 22), as well as ovarian benign tumors (n = 8), were enrolled in the study. Apoptosis of and Fas expression on T cells from peripheral blood and peritoneal fluids were assessed by flow cytometry. Soluble Fas level was assayed using an ELISA kit. The effects of peritoneal fluid on Jurkat cell apoptosis with or without depletion of sFas were evaluated and compared in vitro.Results: The sFas level and apoptosis of T cells in peripheral blood and peritoneal fluid from stages III-IV ovarian carcinoma were significantly higher than those from stages I-II ovarian carcinoma (p < 0.01 in all instances) and benign ovarian tumor (p < 0.01 in all instances). In peritoneal fluid, the sFas level and apoptosis of T cells from stages I-II ovarian carcinoma were significantly higher than those from benign ovarian tumor (p < 0.01 in all instances), and the Fas expression on T cells from ovarian carcinoma were higher than those from benign ovarian tumor (p < 0.05 in all instances). There was a positive correlation between the sFas level and the apoptosis of T cells in peritoneal fluids from stages III-IV ovarian carcinoma (r = 0.647, p = 0.001). Peritoneal fluid of ovarian carcinoma could induce significant Jurkat cell apoptosis. The blocking of Fas expression on the Jurkat cell surface, but not the deletion of sFas, may remarkably restrain the apoptosis level.Conclusions: Elevated sFas is correlated with apoptosis of T cells in peripheral blood and peritoneal fluid from ovarian carcinoma. Soluble Fas evidently does not affect T cell apoptosis, which is probably due to elevated Fas expression on T cells. (C) 2007 Elsevier Ireland Ltd. All rights reserved.

Serum Levels of Soluble Fas,soluble Fas Ligand and Soluble IL-2 Receptor in Patients with Coronary Heart Disease

The Significance of Serum IgE Levels for Different Types of Coronary Atherosclerotic Heart Diseases

Relationship Between Serum Concentrations of IL-18, IL-10, IL-6 and Acute Coronary Syndrome

The Changes of Secretory Type Ⅱ Phospholipase A2 in Coronary Heart Disease and Its Relationship with High Sensifive-C Reactive Protein

Serum Soluble CD40L Level and Its Application in Coronary Heart Disease

SFas/sFas-L and Congestive Heart Failure

Changes and Significance of Serum Soluble Fas(sFas) and FasL(sFasL) Levels in Patients with Breast Cancer

Levels of Soluble Interleukin-2 Receptor and Clinical Significance in Patients with Systemic Lupus Erythematosus

Relationships Between Soluble Fas Levels and Breast Diseases

[Serum Levels of Sfas, Sicam-1, IL-18 in Patients with Chronic Hepatitis C and Their Clinical Significance]

Study of Levels of Soluble Fas and β2-microglobium in the Patients with Chronic Congestive Heart Failure

Correlation Between Soluble Fas Level and Apoptosis of T Cells in Ovarian Carcinoma.

Levels of fibrinogen, D-Dimer and high-sensitivity C-reactive protein in serum of patients with coronary atherosclerotic heart disease

Chemokine CXCL16 Expression in Serum of Patients with Coronary Artery Disease

Serum fgl2 levels elevated in patients with acute coronary syndrome (ACS)

Expression of sFas and sFasL in breast cancer and their clinical significance

The Significance of Plasma Levels of Sfas and Sfasl in Patients with Heart Failure

Relations Between Soluble Fas Ligard and Other Cytokines with Dilated Cardiomyopathy

The Detection and Clinical Signiflcance of Sfas and TNF-α in the Serums of Patients with Chronic Obstructive Pulmonary Disease

The significant increase of FcγRIIIA (CD16), a sensitive marker, in patients with coronary heart disease.

The Variation and Significance of Plasma Hs-Crp,il-6 and Sil-6R Levels in Coronary Heart Disease Patients